Clinical Trials · NCT02177773

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

TerminatedPhase 1/Phase 2Octreotide (Prohibited)
Phase
Phase 1/Phase 2
Recruitment status
Terminated
Sponsor
University of California, San Francisco
Enrollment
300
Start date
Jun 2014
Locations
1 site, United States
Primary endpoint
Number of Lesions as Determined by Gallium Ga 68-DOTA-TOC Positron Emission Tomography (PET) Imaging
View Octreotide compound reference